Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States
BACKGROUND: Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This mo...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Published: |
Oxford University Press
2020
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/25880/ https://doi.org/10.1093/cid/ciaa142 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.um.eprints.25880 |
---|---|
record_format |
eprints |
spelling |
my.um.eprints.258802021-04-21T03:56:43Z http://eprints.um.edu.my/25880/ Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States Zelenev, Alexei Li, Jianghong Shea, Portia Hecht, Robert Altice, Frederick L. R Medicine BACKGROUND: Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This modeling study estimates the impact of scaling up the combination of OAT and SSPs with HCV TasP in a network of people who inject drugs (PWID) in the United States. METHODS: Using empirical data from Hartford, Connecticut, we deployed a stochastic block model to simulate an injection network of 1574 PWID. We used a susceptible-infected model for HCV and human immunodeficiency virus to evaluate the effectiveness of several HCV TasP strategies, including in combination with OAT and SSP scale-up, over 20 years. RESULTS: At the highest HCV prevalence (75%), when OAT coverage is increased from 10% to 40%, combined with HCV treatment of 10% per year and SSP scale up to 40%, the time to achieve microelimination is reduced from 18.4 to 11.6 years. At the current HCV prevalence (60%), HCV TasP strategies as low as 10% coverage per year may achieve HCV microelimination within 10 years, with minimal impact from additional OAT scale-up. Strategies based on mass initial HCV treatment (50 per 100 PWID the first year followed by 5 per 100 PWID thereafter) were most effective in settings with HCV prevalence of 60% or lower. CONCLUSIONS: Scale-up of HCV TasP is the most effective strategy for microelimination of HCV. OAT scale-up, however, scale-up may be synergistic toward achieving microelimination goals when HCV prevalence exceeds 60% and when HCV treatment coverage is 10 per 100 PWID per year or lower. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Oxford University Press 2020 Article PeerReviewed Zelenev, Alexei and Li, Jianghong and Shea, Portia and Hecht, Robert and Altice, Frederick L. (2020) Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States. Clinical Infectious Diseases, 72 (5). pp. 755-763. ISSN 1058-4838 https://doi.org/10.1093/cid/ciaa142 doi:10.1093/cid/ciaa142 |
institution |
Universiti Malaya |
building |
UM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Malaya |
content_source |
UM Research Repository |
url_provider |
http://eprints.um.edu.my/ |
topic |
R Medicine |
spellingShingle |
R Medicine Zelenev, Alexei Li, Jianghong Shea, Portia Hecht, Robert Altice, Frederick L. Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
description |
BACKGROUND: Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This modeling study estimates the impact of scaling up the combination of OAT and SSPs with HCV TasP in a network of people who inject drugs (PWID) in the United States. METHODS: Using empirical data from Hartford, Connecticut, we deployed a stochastic block model to simulate an injection network of 1574 PWID. We used a susceptible-infected model for HCV and human immunodeficiency virus to evaluate the effectiveness of several HCV TasP strategies, including in combination with OAT and SSP scale-up, over 20 years. RESULTS: At the highest HCV prevalence (75%), when OAT coverage is increased from 10% to 40%, combined with HCV treatment of 10% per year and SSP scale up to 40%, the time to achieve microelimination is reduced from 18.4 to 11.6 years. At the current HCV prevalence (60%), HCV TasP strategies as low as 10% coverage per year may achieve HCV microelimination within 10 years, with minimal impact from additional OAT scale-up. Strategies based on mass initial HCV treatment (50 per 100 PWID the first year followed by 5 per 100 PWID thereafter) were most effective in settings with HCV prevalence of 60% or lower. CONCLUSIONS: Scale-up of HCV TasP is the most effective strategy for microelimination of HCV. OAT scale-up, however, scale-up may be synergistic toward achieving microelimination goals when HCV prevalence exceeds 60% and when HCV treatment coverage is 10 per 100 PWID per year or lower. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
format |
Article |
author |
Zelenev, Alexei Li, Jianghong Shea, Portia Hecht, Robert Altice, Frederick L. |
author_facet |
Zelenev, Alexei Li, Jianghong Shea, Portia Hecht, Robert Altice, Frederick L. |
author_sort |
Zelenev, Alexei |
title |
Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
title_short |
Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
title_full |
Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
title_fullStr |
Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
title_full_unstemmed |
Modeling combination Hepatitis C virus treatment and prevention strategies in a network of people who inject drugs in the United States |
title_sort |
modeling combination hepatitis c virus treatment and prevention strategies in a network of people who inject drugs in the united states |
publisher |
Oxford University Press |
publishDate |
2020 |
url |
http://eprints.um.edu.my/25880/ https://doi.org/10.1093/cid/ciaa142 |
_version_ |
1698697313401176064 |
score |
13.19449 |